a glycosphingolipid substrate not detectable in normal lung, vessel or cardiac tissues, was found increased only in the lung and right heart tissues. Morphologic and chemical examination of cardiac and systemic vessels demonstrated accumulation of trihexosyl ceramide in lysosomes of the vascular endothelium. These studies demonstrate that the progressive accumulation of trihexosyl ceramide in the lysosomes of the cardiac structures and vascular system leads to the multiple cardiovascular manifestations of Fabry disease. zygous female.' In addition, these authors reviewed the cardiac manifestations of Fabry disease and suggested the need for further studies of the valvular involvement.
In this report we describe the cardiac findings in two hemizygous males with Fabry disease, with particular emphasis on the clinical, morphologic and biochemical involvement of their valvular abnormalities. We demonstrate that the valvular anomalies in this disease result primarily from the accumulation of trihexosyl ceramide in hypertrophied lysosomes of the cardiac valves.
Materials and Methods

Patient Material
Two hemizygous males with primary cardiac involvement were evaluated at the University of Minnesota Hospitals. Clinical hemizygosity for Fabry disease was confirmed biochemically. The levels of a-galactosidase A activity were determined in plasma, isolated leukocytes, isolated erythrocyte membranes or cultured skin fibroblasts by the methods of Desnick et al. 4 The concentrations of trihexosyl ceramide were determined in plasma9 and urinary sediment.10' 1 Biochemical studies were performed on cardiac and lung tissues obtained within one hour of death from patient 1 and from age and sex-matched individuals who died from noncardiac causes.
Histochemical and Ultrastructural Studies
For light microscopy, small portions of various cardiac tissues were fixed in buffered 10% formalin and sections were stained with hematoxylin-eosin, Sudan black B, and periodic acid-Schiff before and following digestion with diastase. For electron microscopy, portions of fresh cardiac and vessel tissues were fixed in Millonig's buffer containing 1.25% glutaraldehyde and 1.25% osmic acid. After one hour, the tissues were dehydrated in graded alcohols and propylene oxide and then embedded in Epon. Table I shows the levels of a-galactosidase A and B activities in the plasma, leukocytes, isolated erythrocyte mem- branes and myocardium of patients 1 and 2 and normal individuals. No a-galactosidase A activity was detected in these sources from the hemizygous males compared to those of normal individuals. The levels of trihexosyl ceramide in plasma and urinary sediment were increased significantly in patients 1 and 2, thereby confirming the enzymatic diagnosis. Table 2 shows the concentrations of neutral glycosphingolipids in the cardiac valves from patient 1 and from agematched normal male controls. The levels of the ac- was not present. The right pulmonary artery measured 6 mm in diameter and the arterial structure from which it originated measured 2.5-3 mm in diameter. A thrill was not palpable in the right pulmonary artery at the time of operation, suggesting that the right ductus had closed. A 3 mm, end-to-side anastomosis was made between the right pulmonary artery and the ascending aorta ( fig. 3 ). Immediately after completion of the anastomosis, a thrill was present in the right pulmonary artery and the arterial PO2 increased to, and remained in the range of 35-50 throughout the remainder of the patient's hospitalization. When observed six months after operation, the patient was acyanotic.
Comment
Origin of one pulmonary artery from the homolateral ductus arteriosus is not an unusual congenital anomaly but bilateral origin of the pulmonary arteries from the homolateral ducti arteriosi is rare. To our knowledge, the first report of this condition was that of Murray and associates,2 who described two cases.
In a review of 262 patients with discontinuity between the heart and the pulmonary arteries, Berry and associates3 reported that only nine patients did not have continuity between the right and left pulmonary arteries, and in only four of these patients was there bilateral origin of the pulmonary arteries from the homolateral ducti. In the 180 pathological specimens of truncus arteriosus communis cumulated substrate, trihexosyl ceramide, were 5370, 4380, 3830, and 3550 nanomoles/g wet weight in the mitral, aortic, tricuspid, and pulmonary valves, respectively; these values were more than 245-, 175-, 225-, and 185-fold greater than the respective normal adult mean levels. The concentrations of glucosyl ceramide in the valves of the hemizygote were within normal range. However, there were consistent nonspecific increases in the levels of the glycosphingolipids distal and proximal to the metabolic block; the levels of lactosyl and tetrahexosyl ceramides in the valves from patient I were 4 to 18-and 4 to 7-fold greater than the respective normal adult mean values.
Similarly, the concentrations of the neutral glycosphingolipids in the atria, ventricles, selected vessels and lung tissue from patient I and normal adult individuals are shown in table 3 . Each tissue analyzed from the hemizygote had a marked accumulation of the Fabry glycosphingolipid. In the right and left atria and the right and left ventricles the concentrations of trihexosyl ceramide were approximately 450-, 190-, 565-and 650-fold greater than the mean levels in the respective myocardial tissues from normal adult hearts. Small, nonspecific increases in the levels of the other glycosphingolipids in the myocardial tissues from the hemizygote were observed compared to the respective mean adult normal values.
The cardiac vessels studied were also found to have markedly increased levels of trihexosyl ceramide; the levels in the aorta, pulmonary artery and coronary artery were more than 25-, 85-and 245-fold greater than the normal mean adult values, respectively. In addition, the trihexosyl ceramide level in the lung tissue from patient 1 was more than 15-fold greater than the normal mean value. The concentrations of the other neutral glycosphingolipids in these sources were within or only slightly greater than their respective normal adult ranges (table 3) .
In addition to the marked accumulation of trihexosyl ceramide in each tissue analyzed from patient 1, a selective deposition of the glycosphingolipid substrate, digalactosyl ceramide, was found. Table 4 shows that digalactosyl ceramide was detected only in the right heart structures and lung from patient 1 with decreasing levels in the direction of blood flow. The concentrations in the right atrium, tricuspid valve, right ventricle, pulmonary artery and lung tissue were 268, 113, 61, 55 and I1 nmoles/g wet weight, respectively. Galactosyl ceramide was also found in the tricuspid valve and pulmonary artery from patient 1 (table 4) . Digalactosyl analyzed, it was found in the right atrium, tricuspid valve, right ventricle, pulmonary artery and lung tissues from patient 1, in decreasing concentrations, respectively. Since it is unlikely that the intrinsic glycosphingolipid content of the right heart structures would differ from those of the left in Fabry disease, these findings require an alternate explanation. It is tempting to speculate that the source of digalactosyl ceramide in the right heart structures of patient I was derived from the marked deposition in his kidneys. It is conceivable that the accumulated renal digalactosyl ceramide gained access to the circulation and was delivered directly to the right heart structures and subsequently to the reticuloendothelial cells of the lung. This explanation is consistent with the facts that 1) the relative concentration of digalactosyl ceramide in these structures decreased in the direction of blood flow, 2) no digalactosyl ceramide was detected in any of the left heart structures, and 3) a significant concentration of the substrate was detected in the pulmonary tissue from patient 1 (table 4) . These ultrastructural and biochemical findings demonstrate that the valvular and other cardiac abnormalities in Fabry disease result from the pathologic accumulation of neutral glycosphingolipids in the lysosomes of the cardiovascular system. Characterization of these abnormalities has become more important since current investigations attempting to correct the metabolic defect by enzyme replacement therapy6 27-29 are encouraging and future trials may document their biochemical and clinical effectiveness. Clearly, early intervention by enzyme therapeutic endeavors will be requisite to potentially alter the morbidity and/or mortality of the cardiovascular abnormalities in these patients.
